

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number



| | | | |
|---|---|---|---|
| Substitute for form 1449APTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known Application Number 10/660,131 Filing Date September 11, 2003 First Named Inventor David H. Munn Group Art Unit Unassigned Examiner Name Unassigned R. K. Berry Attorney Docket Number M0351-287806 Express Mail Certificate EV 127 541 682 US | |
| Sheet | 1 | of | 9 |

| U.S. PATENT DOCUMENTS | | | | | | |
|-----------------------|-----------------------|----------------------|-----------------------------------|---|---|--|
| Examiner Initials* | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication Cited Document MM-DD-YYYY | Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear |
| | | Number | Kind Code ² (if known) | | | |
| R. K. Berry | 1. | 5,582,831 | | Shinitzky, Meir | 12/10/96 | |
| | 2. | 5,648,219 | | MacKay, V.L. et al. | 07/15/97 | |
| | 3. | 5,849,589 | | Tedder, T.F. et al. | 12/15/98 | |
| | 4. | 5,851,756 | | Steinman, R.M. et al. | 12/22/98 | |
| | 5. | 5,871,728 | | Thomson, A.W. et al. | 02/15/99 | |
| | 6. | 5,994,126 | | Steinman, R.M. et al. | 11/30/99 | |
| | 7. | 6,008,004 | | Olweus, Johanna et al | 12/28/99 | |
| | 8. | 6,080,409 | | Laus, R. et al. | 06/27/00 | |
| | 9. | 6,194,204 | | Crawford, K.D. et al. | 02/27/01 | |
| | 10. | 6,210,662 | | Laus, R. et al. | 04/03/01 | |
| | 11. | 6,224,859 | | Thomson, A.W. et al. | 05-01-01 | |
| | 12. | 6,228,640 | | Cezayirli, C. et al. | 05/08/01 | |
| | 13. | 6,274,378 | | Steinman, R.M. et al | 08/14/01 | |
| | 14. | 6,290,972 | B1 | Armitage, R.J. et al. | 09/18/01 | |
| | 15. | 6,395,876 | | Munn, D. et al. | 05-28-02 | |
| | 16. | 6,451,840 | B1 | Munn, D. et al. | 09-17-02 | |
| | 17. | 2001/0001040 A1 | | Munn, D. et al. | 05-10-01 | |

| FOREIGN PATENT DOCUMENTS | | | | | | | |
|--------------------------|-----------------------|-------------------------|---------------------|-----------------------------------|---|--|---|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Office ³ | Number ⁴ | Kind Code ² (if known) | | | |
| | | | | | | | |

| | | | |
|--------------------|-------------|-----------------|---------|
| Examiner Signature | R. K. Berry | Date Considered | 8/22/06 |
|--------------------|-------------|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|---|---|--------------------------|------------------------------|
| Substitute for form 1449APTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/660,131 |
| | | Filing Date | September 11, 2003 |
| | | First Named Inventor | David H. Munn |
| | | Group Art Unit | Unassigned |
| | | Examiner Name | Unassigned <i>R. DeBerry</i> |
| | | Attorney Docket Number | M0351-287806 |
| Sheet | 2 | of | 9 |
| | | Express Mail Certificate | EV 127 541 682 US |

| OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| <i>MO</i> | 18 | ALBERT, M. L., Dendritic cell maturation is required for the cross-tolerization of CD8 ⁺ T cells, <i>Nature Immunol.</i> , 2 , 1010-1017, 2001 | |
| | 19 | ALEXANDER, A. M. et al., Indoleamine 2,3-Dioxygenase expression in transplanted NOD islets prolongs graft survival after adoptive transfer of diabetogenic splenocytes, <i>Diabetes</i> , 51 :356-364, 2002 | |
| | 20 | BANCHEREAU, J. et al., Immune and clinical responses in patients with metastatic melanoma to CD34 ⁺ progenitor-derived dendritic cell vaccine, <i>Cancer Res.</i> , 61 , 6451-6458, 2001 | |
| | 21 | BANKENSTEIN, T. et al, Cross-priming versus cross-tolerance: are two signals enough?, <i>Trends in Immunol.</i> , 23 , 171-173, 2002 | |
| | 22 | BAX, A. et al., MLEV-17-based two-dimensional homonuclear magnetization transfer spectroscopy, <i>J. Magn. Reson.</i> , 65 : 355-360, 1985 | |
| | 23 | BELL, D. et al., In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas, <i>J. Exp. Med.</i> , 190 , 1417-1426, 1999 | |
| | 24 | BENNETT, S. R. et al., Help for cytotoxic-T-cell responses is mediated by CD40 signalling, <i>Nature</i> , 393 , 478-480, 1998 | |
| | 25 | BODENHAUSEN, G. et al., Natural abundance Nitrogen-15 NMR by enhanced heteronuclear spectroscopy, <i>Natural Chem. Phys. Lett.</i> , 69 : 185-189, 1980 | |
| | 26 | CADY, S. G. et al., 1-Methyl-DL-tryptophan, β -(3-Benzofuranyl)-DL-alanine (the Oxygen Analog of Tryptophan), and β -[3-Benzo(b)thienyl]-DL-alanine (the Sulfur Analog of Tryptophan) are competitive inhibitors of Indoleamine 2,3-Dioxygenase, <i>Arch. Biochem. Biophys.</i> , 291 , 326-333, 1991 | |
| | 27 | CELLA, M. et al., Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation, <i>J. Exp. Med.</i> , 184 , 747-752, 1996 | |
| <i>MO</i> | 28 | CELLA, M. et al., Plasmacytoid monocytes migrate to inflamed | |

R M DeBerry 8/22/06

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|---|--------|--------------------------|-----------------------------|
| Substitute for form 1449APTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/660,131 |
| | | Filing Date | September 11, 2003 |
| | | First Named Inventor | David H. Munn |
| | | Group Art Unit | Unassigned <i>1047</i> |
| | | Examiner Name | Unassigned <i>R. DeBery</i> |
| | | Attorney Docket Number | M0351-287806 |
| Sheet | 3 of 9 | Express Mail Certificate | EV 127 541 682 US |

| | | | |
|---------------------------|----|--|--|
| | | lymph nodes and produce large amounts of type I interferon, <i>Nature Medicine</i> , 5 , 919-923, 1999 | |
| <i>[Handwritten mark]</i> | 29 | CHEN, S., et al., In vivo inhibition of CC and CX3C Chemokine-induced Leukocyte infiltration and attenuation of glomerulonephritis in Wistar-Kyoto (WKY) rats by vMIP-II, <i>J. Exp. Med.</i> , 188 : 193-198 (1998) | |
| | 30 | CHEN, W. et al., TGF- β released by apoptotic T cells contributes to an immunosuppressive milieu, <i>Immunity</i> , 22 :14, 715-725, 2001 | |
| | 31 | COBBOLD, S. et al., Infectious tolerance, <i>Curr. Opin. Immunol.</i> , 10 , 518-524, 1998 | |
| | 32 | CORNILESCU, G. et al., Protein backbone angle restraints from searching a database for chemical shift and sequence homology, <i>J. Biomol. NMR</i> , 13 : 289-302, 1999 | |
| | 33 | CURIEL, T. J. et al., Tumor immunotherapy: inching toward the finish line, <i>J. Clin. Invest.</i> , 109 , 311-312, 2002 | |
| | 34 | DHODAPKAR, M. V. et al., Mature dendritic cells boost functionally superior CD8 ⁺ T-cell in humans without foreign helper epitopes, <i>J. Clin. Invest.</i> , 105 , R9-R14, 2000 | |
| | 35 | DHODAPKAR, M. V. et al., Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells, <i>J. Exp. Med.</i> , 193 , 233-238, 2001 | |
| | 36 | DOAN, T. et al., Peripheral tolerance to human papillomavirus E7 oncoprotein occurs by cross-tolerization, is largely Th-2-independent, and is broken by dendritic cell immunization, <i>Cancer Res.</i> , 60 , 2810-2815, 2000 | |
| | 37 | DONG et al., B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion, <i>Nature Med.</i> , 5 , 1365-1369, 1999 | |
| | 38 | DZIOONEK, A. et al., BDCA-2, BDCA-3, and BDCA-4: Three markers for distinct subsets of dendritic cells in human peripheral blood, <i>J. Immunol.</i> , 165 , 6037-6046, 2000 | |
| | 39 | FACCHETTI, F. et al., Plasmacytoid monocytes (so-called plasmacytoid T cells) in Hodgkin's disease, <i>J. Pathol.</i> , 158 , 57-65, 1989 | |
| | 40 | FALLARINO, F. et al., Functional expression of indoleamine 2,3-dioxygenase by murine CD8 α ⁺ dendritic cells, <i>Internat Immunol.</i> , 14 (1), 65-68, 2002 | |
| <i>[Handwritten mark]</i> | 41 | FIOCCHI, C., TGF- β /Smad signaling defects in inflammatory bowel disease: mechanisms and possible novel therapies for | |

Rm DeBery

8/22/06

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|---|--------------------------|--------------------------|-----------------------|
| Substitute for form 1449APTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/660,131 |
| | | Filing Date | September 11, 2003 |
| | | First Named Inventor | David H. Munn |
| | | Group Art Unit | Unassigned 1647 |
| | | Examiner Name | Unassigned R. DeBerno |
| | | Attorney Docket Number | M0351-287806 |
| Sheet 4 of 9 | Express Mail Certificate | EV 127 541 682 US | |

| | | | |
|----|--|--|--|
| | | chronic inflammation, <i>J. Clin. Invest.</i> , 108 , 523-526, 2001 | |
| 42 | | GALLUCCI, S. et al., Natural adjuvants: Endogenous activators of dendritic cells, <i>Nat. Med.</i> , 5 , 1249-1255, 1999 | |
| 43 | | GORCZYNSKI, R. et al., Dendritic cells expressing TGFβ/IL-10, and CHO cells with OX-2, increase graft survival, <i>Transplantation Proceedings</i> , 33 , 1565-1566, 2001 | |
| 44 | | GROHMANN, U. et al., IL-6 inhibits the tolerogenic function of CD8α ⁺ dendritic cells expressing indoleamine 2,3-dioxygenase, <i>J. Immunol.</i> , 167 , 708-714, 2001 | |
| 45 | | GROUARD, G. et al., The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand, <i>J. Exp. Med.</i> , 185 , 1101-1111, 1997 | |
| 46 | | HEISER, A. et al., Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors, <i>J. Clin. Invest.</i> , 109 , 409-417, 2002 | |
| 47 | | HONEY, K. et al., Dominant regulation: a common mechanism of monoclonal antibody induced tolerance?, <i>Immunol. Res.</i> , 20 , 1-14, 1999 | |
| 48 | | HORUZSKO, A. et al., Maturation of antigen presenting cells is compromised in HLA-G transgenic mice, <i>Internat Immunol.</i> , 13 , 385-394, 2001 | |
| 49 | | HWU, P. et al., Indoleamine 2,3-Dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation, <i>J. Immunol.</i> , 164 :3596-3599, 2000 | |
| 50 | | IWASAKI, A. et al., Localization of distinct peyer's patch dendritic cell subsets and their recruitment by chemokines macrophage inflammatory protein (MIP)-3α, MIP-3β, and secondary lymphoid organ chemokine, <i>J. Exp. Med.</i> , 191 , 1381-1393, 2000 | |
| 51 | | JONULEIT, H. et al., Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions, <i>Eur. J. Immunol.</i> , 27 , 3135-3142, 1997 | |
| 52 | | JONULEIT, H. et al., Dendritic cells as a tool to induce anergic and regulatory T cells, <i>Trends Immunol.</i> , 22 , 394-400, 2001 | |
| 53 | | KIKUCHI, T. et al., Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors, <i>Blood</i> , 96 , 91-99, 2000 | |
| 54 | | KOURILSKY, P. et al., Cytokine fields and the polarization of | |

R M DeBerno 8/22/06

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|---|--------|--------------------------|-------------------------------|
| Substitute for form 1449APTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/660,131 |
| | | Filing Date | September 11, 2003 |
| | | First Named Inventor | David H. Munn |
| | | Group Art Unit | Unassigned |
| | | Examiner Name | Unassigned <i>R. O. Berry</i> |
| | | Attorney Docket Number | M0351-287806 |
| Sheet | 5 of 9 | Express Mail Certificate | EV 127 541 682 US |

| | | | |
|------------|----|---|--|
| | | the immune response, <i>Trends in Immunol.</i> , 22 , 502-509, 2001 | |
| <i>pgs</i> | 55 | KUDO, Y. et al., Human placental indoleamine 2,3-dioxygenase: cellular location and characterization of an enzyme preventing fetal rejection, <i>Biochem, Biophys. Acta</i> , 1500 , 119-124, 2000 | |
| 7* | 56 | LEE et al., Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division, <i>Immunol.</i> , 107 : 452-460 (2002) | |
| | 57 | LIU, Y. J., Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity, <i>Cell</i> , 106 , 259-262, 2001 | |
| | 58 | MALLOY, K. G. et al., Regulatory T cells in the control of immune pathology, <i>Nature Immunol.</i> , 2 , 816-822, 2001 | |
| | 59 | MELLOR, A.L. et al., Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy, <i>Nat. Immunol.</i> 2 : 64-68 (2001) | |
| | 60 | MELLOR, A. L. et al., Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses, <i>J. Immunol.</i> , 168 , 3771-3776, 2002 | |
| | 61 | MIKI, T. et al., Blockade of tryptophan catabolism prevents spontaneous tolerogenicity of liver allografts, <i>Transplantation Proceedings</i> , 33 , 129-130, 2001 | |
| | 62 | MULLER, A. et al, Involvement of chemokine receptors in breast cancer metastasis, <i>Nature</i> , 410 : 50-56, 2001 | |
| | 63 | MUNN, D. H. et al., Prevention of allogeneic fetal rejection by tryptophan catabolism, <i>Science</i> , 281 , 1191-1193, 1998 | |
| | 64 | MUNN, D. H. et al., Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase, <i>Science</i> , 297 , 1867-1870, 2002 | |
| | 65 | MUNN, D. H. et al., Inhibition of T cell proliferation by macrophage tryptophan catabolism, <i>J. Exp. Med.</i> , 189 , 1363-1372, 1999 | |
| | 66 | NEUHAUS, D. et al, <i>The Nuclear Overhauser Effect in Structural and Conformational Analysis</i> , VCH New York, Chapter 8, The Two- Dimensional NOESY Experiment, 1989, pp. 253-305 | |
| <i>100</i> | 67 | OCHSENBEIN, A. F. et al., Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction, <i>Nature</i> , 411 , 1058-1064, 2001 | |
| | 68 | OLWEUS, J. et al., Dendritic cell ontogeny: A human dendritic | |

RN Berry 8/22/06

Please type a plus sign (+) inside this box → ☐

PTO/SB/O&A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|---|--|--------------------------|---------------------|
| Substitute for form 1449APTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/660,131 |
| | | Filing Date | September 11, 2003 |
| | | First Named Inventor | David H. Munn |
| | | Group Art Unit | Unassigned 1/45 |
| | | Examiner Name | Unassigned R DeBery |
| | | Attorney Docket Number | M0351-287806 |
| Sheet 6 of 9 | Express Mail Certificate EV 127 541 682 US | | |

| | | | |
|----|--|---|--|
| | | cell lineage of myeloid origin, <i>Proc. Natl. Acad. Sci. USA</i> , 94 , 12551-12556, 1997 | |
| 69 | | PALCZEWSKI, K. et al., Crystal structure of rhodopsin: A G protein—coupled receptor, <i>Science</i> 289 : 739-745, 2000 | |
| 70 | | PICKL, W. F. et al., Molecular and functional characteristics of dendritic cells generated from highly purified CD14 ⁺ peripheral blood monocytes, <i>J. Immunol.</i> , 157 , 3850-3859, 1996 | |
| 71 | | PIOTTO, M. et al, Gradient-tailored excitation for single-quantum NMR spectroscopy of aqueous solutions, <i>J. Biomol. NMR.</i> , 2 : 661-665, 1992 | |
| 72 | | REDDY, A. et al., A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells, <i>Blood</i> , 90 , 3640-3646, 1997 | |
| 73 | | RIDGE, J. P. et al., A conditioned dendritic cell can be a temporal bridge between a CD4 ⁺ T-helper and a T-killer cell, <i>Nature</i> , 393 , 474-478, 1998 | |
| 74 | | SAKAGUCHI, S., Regulatory T cells: key controllers of immunologic self-tolerance, <i>Cell</i> , 101 , 455-458, 2000 | |
| 75 | | SALI, A. et al., Definition of general topological equivalence in protein structures, <i>J. Mol. Biol.</i> , 212 , 403-428, 1990 | |
| 76 | | SCHOENBERGER, S. P. et al., T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions, <i>Nature</i> , 393 , 480-483, 1998 | |
| 77 | | SHEVACH, E. M., Certified professionals: CD4+CD25+ suppressor T cells, <i>J. Exp. Med.</i> , 193 , F41-F45, 2001 | |
| 78 | | SHORTMAN, K. et al., Immunity or tolerance? That is the question for dendritic cells, <i>Nature Immunol.</i> , 2 , 988-989, 2001 | |
| 79 | | SHORTMAN, K. et al., Mouse and human dendritic cell subtypes, <i>Nature Reviews: Immunology</i> , 2 , 151-161, 2002 | |
| 80 | | SMYTH, M. J., et al., A fresh look at tumor immunosurveillance and immunotherapy, <i>Nature</i> , 2 , 293-298, 2001 | |
| 81 | | SOTOMAYER, E. J. et al., Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression, <i>Blood</i> , 98 , 1070-1077, 2001 | |
| 82 | | SOZZANI, S. et al., The role of chemokines in the regulation of dendritic cell trafficking, <i>J. Leukocyte Biol.</i> , 66 , 1-9, 1999 | |
| 83 | | SPATOLA, A.F. et al, Rediscovering an endothelin antagonist | |

KM DeBery 8/22/06

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|---|---|--------------------------|----------------------|
| Substitute for form 1449APTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | |
| | | Application Number | 10/660,131 |
| | | Filing Date | September 11, 2003 |
| | | First Named Inventor | David H. Munn |
| | | Group Art Unit | Unassigned 1647 |
| | | Examiner Name | Unassigned L. DeBery |
| | | Attorney Docket Number | M0351-287806 |
| Sheet | 7 | of | 9 |
| | | Express Mail Certificate | EV 127 541 682 US |

| | | | |
|--|----|---|--|
| | | (BQ-123): a self-deconvoluting cyclic pentapeptide library, <i>J. Med. Chem.</i> , 39 : 3842-3846, 1996 | |
| | 84 | SPATOLA, A.F., Chemistry and Biochemistry of Amino Acids, Peptides, and Proteins, ed. B. Weinstein et al, New York, Vol. VII, pp. 267-357, 1983 | |
| | 85 | STAVELEY-O'CARROLL, K. et al., Induction of antigen-specific T cell anergy: An early event in the course of tumor progression, <i>Proc. Natl. Acad. Sci. USA</i> , 95 , 1178-1183, 1998 | |
| | 86 | SUMMERS, K. L. et al., Phenotypic characterization of five dendritic cell subsets in human tonsils, <i>Am. J. Pathol.</i> , 159 , 285-295, 2001 | |
| | 87 | SUTMULLER, R. P. M. et al., Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25 ⁺ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses, <i>J. Exp. Med.</i> , 194 , 823-832, 2001 | |
| | 88 | SZABOLCS, P. et al., Dendritic cells and macrophages can mature independently from a human bone marrow-derived, post-colony-forming unit intermediate, <i>Blood</i> , 87 , 4520-4530, 1996 | |
| | 89 | TARAZONA, R. et al, Effects of different antigenic microenvironments on the course of CD8 ⁺ T cell responses in vivo, <i>Int. Immunol.</i> , 8 , 351-358, 1996 | |
| | 90 | TAYLOR, M. W. et al., Relationship between interferon- γ , indoleamine 2,3-dioxygenase, and tryptophan catabolism, <i>FASEB J.</i> , 5 , 2516-2522, 1991 | |
| | 91 | THOMPSON, A. W. et al., Are dendritic cells the key to liver transplant tolerance?, <i>Immunol. Today</i> , 20 , 27-31, 1999 | |
| | 92 | TODRYK, S., A sense of tumour for the immune system, <i>Immunol.</i> , 107 , 1-4, 2002 | |
| | 93 | van ELSAS, A. et al., Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation, <i>J. Exp. Med.</i> , 190 , 355-366, 1999 | |
| | 94 | van ELSAS, A. et al., Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with | |

RM DeBery

8/22/06

Please type a plus sign (+) inside this box → ☐

PTO/SB/OBA (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|---|--------------------------|--------------------------|---------------------|
| Substitute for form 1449APTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/660,131 |
| | | Filing Date | September 11, 2003 |
| | | First Named Inventor | David H. Munn |
| | | Group Art Unit | Unassigned-1647 |
| | | Examiner Name | Unassigned-K. DeBem |
| | | Attorney Docket Number | M0351-287806 |
| Sheet 8 of 9 | Express Mail Certificate | | EV 127 541 682 US |

| | | | |
|--|-----|--|--|
| | | a B16 melanoma vaccine: comparison of prophylaxis and therapy, <i>J. Exp. Med.</i> , 194 , 481-489, 2001 | |
| | 95 | VARONA, R. et al., CCR6-deficient mice have impaired leukocyte homeostasis and altered contact hypersensitivity and delayed-type hypersensitivity responses, <i>J. Clin. Invest.</i> , 107 , R37-R45, 2001 | |
| | 96 | WALDMANN, H. et al., Regulating the immune response to transplants: a role for CD4 ⁺ regulatory cells?, <i>Immunity</i> , 14 , 399-406, 2001 | |
| | 97 | WISHART, D.S. et al., 1H, 13C and 15N chemical shift referencing in biomolecular NMR, <i>J. Biomol. NMR</i> , 6 , 135-140, 1995 | |
| | 98 | YANG, D. et al., Cutting edge: Immature dendritic cells generated from monocytes in the presence of TGF- β 1 express functional C-C chemokine receptor 6, <i>J. Immunol.</i> , 163 , 1737-1741, 1999 | |
| | 99 | ZLOTNIK, A. et al., Chemokines: a new classification system and their role in immunity, <i>Immunity</i> , 12 , 121-127, 2000 | |
| | 100 | MORITA, Y. et al., Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis, <i>J. Clin. Invest.</i> , 107 , 1275-1284, 2001 | |
| | 101 | MORSE, M.A. et al., Technology evaluation: Theratope, Biomira Inc., <i>Curr. Opin. Mol. Ther.</i> , Aug 2(4) :453-458, 2000 | |
| | 102 | MORSE, M. A. et al., Clinical applications of dendritic cell vaccines, <i>Current Opinion in Molecular Therapeutics</i> , 2(1) :20-28, 2000 | |
| | 103 | NAIR, S. K. et al., Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses <i>in vitro</i> using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA, <i>Int. J. Cancer</i> , 82 , 121-124, 1999 | |
| | 104 | POLUEKTOVA, L. Y. et al., Generation of cytotoxic T cells against virus-infected human brain macrophages in a murine model of HIV-1 encephalitis, <i>J Immunol.</i> , 168 :3941-3949, 2002 | |
| | 105 | RONCAROLO, M. G. et al., Differentiation of T regulatory cells by immature dendritic cells, <i>J. Exp. Med.</i> , 193 , F5-F9, 2001 | |
| | 106 | YOON, J.-W. et al., Control of autoimmune diabetes in NOD mice by GAD expression or suppression of β cells, <i>Science</i> , 284 , 1183-1187, 1999 | |

Handwritten signature and date: 8/22/06

Please type a plus sign (+) inside this box → +

PTO/SB/O&A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| Substitute for form 1449APTO <h2 style="text-align: center; margin: 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center; font-size: small;">(use as many sheets as necessary)</p> | <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: left; padding: 2px;">Complete if Known</th> </tr> <tr> <td style="width: 50%; padding: 2px;">Application Number</td> <td style="padding: 2px;">10/660,131</td> </tr> <tr> <td style="padding: 2px;">Filing Date</td> <td style="padding: 2px;">September 11, 2003</td> </tr> <tr> <td style="padding: 2px;">First Named Inventor</td> <td style="padding: 2px;">David H. Munn</td> </tr> <tr> <td style="padding: 2px;">Group Art Unit</td> <td style="padding: 2px;">Unassigned 1647</td> </tr> <tr> <td style="padding: 2px;">Examiner Name</td> <td style="padding: 2px;">Unassigned R. DeBerry</td> </tr> <tr> <td style="padding: 2px;">Attorney Docket Number</td> <td style="padding: 2px;">M0351-287806</td> </tr> </table> | Complete if Known | | Application Number | 10/660,131 | Filing Date | September 11, 2003 | First Named Inventor | David H. Munn | Group Art Unit | Unassigned 1647 | Examiner Name | Unassigned R. DeBerry | Attorney Docket Number | M0351-287806 |
|--|--|-------------------|--|--------------------|------------|-------------|--------------------|----------------------|---------------|----------------|-----------------|---------------|-----------------------|------------------------|--------------|
| Complete if Known | | | | | | | | | | | | | | | |
| Application Number | 10/660,131 | | | | | | | | | | | | | | |
| Filing Date | September 11, 2003 | | | | | | | | | | | | | | |
| First Named Inventor | David H. Munn | | | | | | | | | | | | | | |
| Group Art Unit | Unassigned 1647 | | | | | | | | | | | | | | |
| Examiner Name | Unassigned R. DeBerry | | | | | | | | | | | | | | |
| Attorney Docket Number | M0351-287806 | | | | | | | | | | | | | | |
| Sheet 9 of 9 | Express Mail Certificate EV 127 541 682 US | | | | | | | | | | | | | | |

| | | |
|--|--|--|
| | | |
| | | |
| | | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08a (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|------|--------------------------|---------------------------|
| Substitute for form 1449A/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Application Number | 0/660,131 |
| | | Filing Date | September 11, 2003 |
| | | First Named Inventor | David H. Munn et al. |
| | | Art Unit | 1646 1647 |
| | | Examiner Name | To be assigned R. DeBerni |
| Sheet 1 | of 2 | Attorney Docket Number | CCR6 (M0351/287806) |

| U.S. PATENT DOCUMENTS | | | | | |
|------------------------|--------------------------|--|--------------------------------|--|---|
| Examiner Initials * | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number - Kind Code ² (if known) | | | |
| RO | 1 | US- 5,885,579 | 03/23/1999 | Linsley et al. | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |


| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|--------------------------|---|-----------------------------------|---|--|----------------|
| Examiner Initials * | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ - Number ⁴ - Kind Code ⁵ (if known) | | | | |
| RO | 1 | WO 01/17558 A2 | 03/15/200 1 | Schering Corporation | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

| | | | |
|-----------------------|-------------------|--------------------|---------|
| Examiner Signature | <i>R. DeBerni</i> | Date Considered | 8/22/06 |
|-----------------------|-------------------|--------------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Institute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

| | |
|------------------------|--------------------------|
| Application Number | 10/660,131 |
| Filing Date | September 11, 2003 |
| First Named Inventor | David H. Munn et al. |
| Art Unit | 1646-1647 |
| Examiner Name | To be assigned R. DeBerg |
| Attorney Docket Number | CCR6 (M0351/287806) |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|------------------------|--------------------------|---|----------------|
| MD | 1 | International Search Report mailed 08/19/04 corresponding to PCT/US03/28349 considered DO NOT PRINT | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|-----------------------|--------------|--------------------|---------|
| Examiner Signature | R. M. DeBerg | Date Considered | 8/22/06 |
|-----------------------|--------------|--------------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2